Widely used:Recently Viewed
Clear AllToday’s Range
52 Week Range
Liquidity
Market cap
$287 Mln
P/E Ratio
--
P/B Ratio
25.37
Industry P/E
--
Debt to Equity
-0
ROE
-34.89 %
ROCE
357.94 %
Div. Yield
0 %
Book Value
--
EPS
-5.31
CFO
$-539.95 Mln
EBITDA
$-747.10 Mln
Net Profit
$-917.04 Mln
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|
|---|---|---|---|---|---|---|---|
|
Phathom Pharmaceuticals (PHAT)
| -48.89 | -37.97 | -36.74 | -54.79 | -31.27 | -35.63 | -- |
|
BSE Sensex*
| 2.62 | 3.73 | 5.80 | 8.91 | 11.76 | 20.12 | 11.35 |
|
S&P Small-Cap 600#
| -5.82 | -5.34 | -13.73 | -6.30 | 5.30 | 2.98 | 5.53 |
|
2024
|
2023
|
2022
|
2021
|
2020
|
|
|---|---|---|---|---|---|
|
Phathom Pharmaceuticals (PHAT)
| -10.98 | -18.63 | -42.96 | -40.79 | 6.68 |
|
S&P Small-Cap 600
| 7.01 | 13.89 | -17.42 | 25.27 | 9.57 |
|
BSE Sensex
| 8.10 | 18.74 | 4.44 | 21.99 | 15.75 |
Is there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
3Y Avg -- 5Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Company |
Price ($) | Market Cap ($ Mln) | P/E Ratio | ROE |
|---|---|---|---|---|
| 38.44 | 10,315.11 | 21.27 | 23.13 | |
| 298.18 | 8,705.27 | 22.77 | 66.44 | |
| 27.46 | 10,589.59 | -- | -28.77 | |
| 106.46 | 10,559.67 | 32.44 | 14.16 |
Phathom Pharmaceuticals, Inc., a biopharmaceutical company, develops and commercializes treatments for gastrointestinal diseases. The company develops its products based on vonozopran, an investigational potassium-competitive acid blocker (P-CAB)... that blocks acid secretion in the stomach. Its products under development include VOQUEZNA, which has completed its Phase III clinical trials for the treatment of erosive gastroesophageal reflux disease (GERD) and its Phase II clinical trials for the as-needed dosing for active heartburn episodes; and VOQUEZNA TRIPLE PAK and VOQUEZNA DUAL PAK, which have completed the Phase III clinical trials for the eradication of Helicobacter pylori infection. The company has the rights in the United States, Europe, and Canada for P-CAB. The company was incorporated in 2018 and is headquartered in Florham Park, New Jersey. Address: 100 Campus Drive, Florham Park, NJ, United States, 07932 Read more
President, CEO & Director
Ms. Terrie J. Curran
President, CEO & Director
Ms. Terrie J. Curran
Headquarters
Florham Park, NJ
Website
Our rating system has guided millions of investors in the past 20 years.
The total asset value of Phathom Pharmaceuticals Inc (PHAT) stood at $ 378 Mln as on 31-Dec-24
The share price of Phathom Pharmaceuticals Inc (PHAT) is $4.15 (NASDAQ) as of 28-Apr-2025 16:23 EDT. Phathom Pharmaceuticals Inc (PHAT) has given a return of -31.27% in the last 3 years.
Phathom Pharmaceuticals Inc (PHAT) has a market capitalisation of $ 287 Mln as on 28-Apr-2025. As per Value Research classification, it is a Small Cap company.
Since, TTM earnings of Phathom Pharmaceuticals Inc (PHAT) is negative, P/E ratio is not available.
Step 1. Open a demat account through a broker. You would need to provide your email, PAN, bank account details, aadhar details, etc., for KYC
Step 2. Sign in to the broker’s application through a mobile app or website. Use the Login ID and password provided by your broker.
Step 3. Transfer funds from your bank account into the wallet present in your brokerage account.
Step 4. Search for the Phathom Pharmaceuticals Inc (PHAT) and enter the required number of quantities and click on buy to purchase the shares of Phathom Pharmaceuticals Inc (PHAT).
Phathom Pharmaceuticals, Inc., a biopharmaceutical company, develops and commercializes treatments for gastrointestinal diseases. The company develops its products based on vonozopran, an investigational potassium-competitive acid blocker (P-CAB) that blocks acid secretion in the stomach. Its products under development include VOQUEZNA, which has completed its Phase III clinical trials for the treatment of erosive gastroesophageal reflux disease (GERD) and its Phase II clinical trials for the as-needed dosing for active heartburn episodes; and VOQUEZNA TRIPLE PAK and VOQUEZNA DUAL PAK, which have completed the Phase III clinical trials for the eradication of Helicobacter pylori infection. The company has the rights in the United States, Europe, and Canada for P-CAB. The company was incorporated in 2018 and is headquartered in Florham Park, New Jersey. Address: 100 Campus Drive, Florham Park, NJ, United States, 07932
The CEO & director of Ms. Terrie J. Curran. is Phathom Pharmaceuticals Inc (PHAT), and CFO & Sr. VP is Ms. Terrie J. Curran.
There is no promoter pledging in Phathom Pharmaceuticals Inc (PHAT).
Some of the close peers are:
| Company | Market Cap($ Mln) |
|---|---|
|
1,014
|
|
|
1,003
|
|
|
956
|
|
|
867
|
| Phathom Pharmaceuticals Inc. (PHAT) | Ratios |
|---|---|
|
Return on equity(%)
|
204.89
|
|
Operating margin(%)
|
-474.76
|
|
Net Margin(%)
|
-605.09
|
|
Dividend yield(%)
|
--
|
No, TTM profit after tax of Phathom Pharmaceuticals Inc (PHAT) was $0 Mln.
$0.04
(
